Antimicrobial Agents — MCQs

Q: Which of the following is a known side effect of zidovudine?

Granulocytopenia. Zidovudine (AZT) is a Nucleoside Reverse Transcriptase Inhibitor (NRTI) used in the management of HIV/AIDS. The correct answer is Granulocytopenia because the most significant and dose-limiting toxicity of zidovudine is bone marrow suppression. 1. Why Granulocytopenia is correct: Zidovudine inhibits DNA polymerase-gamma in host cells, leading to mitochondrial toxicity and interference with rapidly dividing cells [1], [2]. This results in significant myelosuppression, manifesting primarily as anemia (macrocytic) and granulocytopenia/neutropenia. This effect is additive when used with other myelosuppressive drugs like ganciclovir or trimethoprim-sulfamethoxazole. 2. Why other options are incorrect: * Headache and Myalgia (Options A & B): While these can occur as non-specific constitutional symptoms during the initiation of therapy, they are not the "signature" or dose-limiting toxicities tested in competitive exams. (Note: Zidovudine causes a specific myopathy, but granulocytopenia is the more classic hematological side effect). * Rashes (Option D): Rashes are more characteristic of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) like Nevirapine (which can cause Stevens-Johnson Syndrome) or the NRTI Abacavir (hypersensitivity reaction). High-Yield Clinical Pearls for NEET-PG: * Mnemonic: Zidovudine causes "Zapped" Bone Marrow (Anemia and Neutropenia). * Drug of Choice: Zidovudine is the preferred drug for preventing vertical transmission (mother-to-child) of HIV during pregnancy and labor. * Lactic Acidosis: Like all NRTIs, it carries a risk of lactic acidosis and hepatic steatosis [2]. * Monitoring: Patients on AZT require regular monitoring of Hemoglobin and Absolute Neutrophil Count (ANC).

Q: What is the drug of choice for neurocysticercosis?

Albendazole. **Explanation:** **Albendazole** is the drug of choice for neurocysticercosis (NCC) caused by the larval stage of *Taenia solium*. The primary reason for its superiority over other agents is its **superior penetration into the Central Nervous System (CNS)**. Albendazole is a prodrug converted to albendazole sulfoxide, which achieves high concentrations in the cerebrospinal fluid (CSF) and brain parenchyma. It is more effective than Praziquantel in reducing the number of viable cysts and controlling seizures, especially in parenchymal NCC. **Analysis of Options:** * **Praziquantel (Option A):** While effective against many trematodes and cestodes, it has lower CNS penetration compared to Albendazole. It is considered a second-line agent or used in combination with Albendazole for heavy cyst burdens (multicystic disease). * **Levamisole (Option C):** Primarily used as an immunomodulator or for Ascaris infections; it has no role in treating NCC. * **Piperazine (Option D):** An older anthelmintic used for *Ascaris* and *Enterobius* by causing flaccid paralysis of the worm; it is ineffective against cysticercosis. **Clinical Pearls for NEET-PG:** 1. **Steroid Co-administration:** Always administer corticosteroids (e.g., Dexamethasone) before or with Albendazole to prevent inflammatory brain edema caused by the death of the larvae (Herxheimer-like reaction). 2. **Duration:** Treatment typically lasts 8–15 days for parenchymal cysts. 3. **Ocular Cysticercosis:** Albendazole is **contraindicated** in ocular cysticercosis as the inflammatory response to dying larvae can cause permanent blindness. Surgical excision is preferred. 4. **Mechanism:** Albendazole works by inhibiting microtubule synthesis (binding to β-tubulin), leading to glucose depletion and death of the parasite.

Q: Ethambutol is safer in a patient with which of the following conditions?

Liver disease. **Explanation:** The correct answer is **Liver disease** because Ethambutol is primarily excreted unchanged by the kidneys (approx. 80%) and undergoes minimal hepatic metabolism. Unlike other first-line anti-tubercular drugs (HRZ—Isoniazid, Rifampicin, and Pyrazinamide), Ethambutol is **not hepatotoxic**. Therefore, it is the drug of choice or a safer alternative when treating tuberculosis in patients with pre-existing chronic liver disease. **Analysis of Incorrect Options:** * **Kidney disease:** Since Ethambutol is mainly excreted via the renal route, it accumulates in renal failure, increasing the risk of dose-dependent toxicity (optic neuritis). Dosage adjustment or avoidance is necessary in renal impairment. * **Gout:** Ethambutol interferes with the renal excretion of uric acid, leading to **hyperuricemia**. This can precipitate an acute attack of gout, making it unsafe for these patients. * **Both liver and kidney disease:** While safe for the liver, its significant risk in renal failure makes this option incorrect. **High-Yield NEET-PG Pearls:** * **Mechanism of Action:** Inhibits **Arabinosyl transferase**, thereby blocking the synthesis of Arabinogalactan in the mycobacterial cell wall. * **Key Side Effect:** **Retrobulbar Optic Neuritis**, manifesting as decreased visual acuity and **Red-Green color blindness**. It is generally reversible upon discontinuation. * **Monitoring:** Monthly visual acuity and color vision testing are mandatory for patients on Ethambutol. * **Pediatric Note:** It is often avoided in young children (usually <6 years) because they cannot reliably report changes in visual acuity or color perception.

Q: Bictegravir was approved by FDA for which of the following indications?

Human Immunodeficiency Virus (HIV). **Explanation:** **Bictegravir** is a potent, second-generation **Integrase Strand Transfer Inhibitor (INSTI)**. It was FDA-approved in 2018 as part of a fixed-dose combination (Bictegravir/Emtricitabine/Tenofovir Alafenamide) for the treatment of **HIV-1 infection** in both treatment-naïve and virologically suppressed patients. **Mechanism of Action:** Bictegravir works by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration into the host cell genome. This prevents the HIV-1 provirus from replicating. **Analysis of Incorrect Options:** * **A. Cystic Fibrosis:** This is a genetic disorder affecting chloride channels (CFTR). Treatment involves CFTR modulators (e.g., Ivacaftor) and antibiotics for lung infections, but not antiretrovirals. * **B. Tuberculosis:** TB is caused by *Mycobacterium tuberculosis* and is treated with RIPE therapy (Rifampin, Isoniazid, Pyrazinamide, Ethambutol). While HIV and TB are common co-infections, Bictegravir itself has no anti-mycobacterial activity. * **C. Hypertension:** This is managed with ACE inhibitors, ARBs, Beta-blockers, or Calcium channel blockers. **High-Yield Clinical Pearls for NEET-PG:** * **Class:** INSTI (Suffix "-tegravir"). Other members include Dolutegravir, Raltegravir, and Elvitegravir. * **Advantages:** Bictegravir has a **high genetic barrier to resistance** and fewer drug-drug interactions compared to older protease inhibitors or Elvitegravir (which requires boosting with Cobicistat). * **Side Effects:** Generally well-tolerated; may cause headache, GI upset, or weight gain. * **Drug Interaction:** Avoid co-administration with polyvalent cations (Mg, Al, Ca) as they can chelate the drug and reduce absorption.

Antimicrobial Agents Indian Medical PG Practice Questions and MCQs

Question 1: Which of the following is a known side effect of zidovudine?

A. Headache
B. Myalgia
C. Granulocytopenia (Correct Answer)
D. Rashes

Explanation: Zidovudine (AZT) is a Nucleoside Reverse Transcriptase Inhibitor (NRTI) used in the management of HIV/AIDS. The correct answer is Granulocytopenia because the most significant and dose-limiting toxicity of zidovudine is bone marrow suppression. 1. Why Granulocytopenia is correct: Zidovudine inhibits DNA polymerase-gamma in host cells, leading to mitochondrial toxicity and interference with rapidly dividing cells [1], [2]. This results in significant myelosuppression, manifesting primarily as anemia (macrocytic) and granulocytopenia/neutropenia. This effect is additive when used with other myelosuppressive drugs like ganciclovir or trimethoprim-sulfamethoxazole. 2. Why other options are incorrect: * Headache and Myalgia (Options A & B): While these can occur as non-specific constitutional symptoms during the initiation of therapy, they are not the "signature" or dose-limiting toxicities tested in competitive exams. (Note: Zidovudine causes a specific myopathy, but granulocytopenia is the more classic hematological side effect). * Rashes (Option D): Rashes are more characteristic of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) like Nevirapine (which can cause Stevens-Johnson Syndrome) or the NRTI Abacavir (hypersensitivity reaction). High-Yield Clinical Pearls for NEET-PG: * Mnemonic: Zidovudine causes "Zapped" Bone Marrow (Anemia and Neutropenia). * Drug of Choice: Zidovudine is the preferred drug for preventing vertical transmission (mother-to-child) of HIV during pregnancy and labor. * Lactic Acidosis: Like all NRTIs, it carries a risk of lactic acidosis and hepatic steatosis [2]. * Monitoring: Patients on AZT require regular monitoring of Hemoglobin and Absolute Neutrophil Count (ANC).

Question 2: Which of the following drug combinations demonstrates antimicrobial synergism?

A. Penicillin plus Streptomycin in subacute bacterial endocarditis (Correct Answer)
B. Ampicillin plus Tetracycline in endocarditis
C. Sulfamethoxazole plus Trimethoprim in urinary tract infections
D. Amphotericin B plus Flucytosine in cryptococcal meningitis

Explanation: **Explanation:** **1. Why Option A is Correct (The Concept of Synergism):** The combination of **Penicillin and Streptomycin** is a classic example of **sequential blockade** leading to bactericidal synergism. Penicillin, a cell wall synthesis inhibitor, damages the bacterial cell wall. This increased permeability allows Streptomycin (an aminoglycoside) to enter the cell more easily and reach its target site (the 30S ribosome) to inhibit protein synthesis. This synergy is clinically vital in treating **Enterococcal Subacute Bacterial Endocarditis (SABE)**, where either drug alone would only be bacteriostatic or ineffective. **2. Analysis of Other Options:** * **Option B (Ampicillin + Tetracycline):** This is an example of **Antagonism**. Ampicillin (bactericidal) requires actively multiplying bacteria to work. Tetracycline (bacteriostatic) inhibits growth, thereby reducing the efficacy of the penicillin. * **Option C & D:** While these combinations are indeed synergistic (Sequential blockade in Cotrimoxazole; increased uptake in Amphotericin + Flucytosine), the question asks for the **most definitive** example of antimicrobial synergism traditionally taught in the context of endocarditis and cell-wall/protein-synthesis interaction. *Note: In many exams, if multiple options show synergism, the Penicillin + Aminoglycoside pair is considered the "gold standard" answer for this concept.* **3. NEET-PG High-Yield Pearls:** * **Synergism Mechanisms:** 1. **Sequential Blockade:** Sulfonamides + Trimethoprim. 2. **Facilitation of entry:** Penicillins + Aminoglycosides. 3. **Inhibition of degrading enzymes:** Amoxicillin + Clavulanic acid. * **Rule of Thumb:** Bactericidal + Bactericidal = Synergistic; Bactericidal + Bacteriostatic = Antagonistic. * **Clinical Exception:** In Meningitis, combinations are used to expand coverage, not necessarily for synergism.

Question 3: What is the drug of choice for neurocysticercosis?

A. Praziquantel
B. Albendazole (Correct Answer)
C. Levamisole
D. Piperazine

Explanation: **Explanation:** **Albendazole** is the drug of choice for neurocysticercosis (NCC) caused by the larval stage of *Taenia solium*. The primary reason for its superiority over other agents is its **superior penetration into the Central Nervous System (CNS)**. Albendazole is a prodrug converted to albendazole sulfoxide, which achieves high concentrations in the cerebrospinal fluid (CSF) and brain parenchyma. It is more effective than Praziquantel in reducing the number of viable cysts and controlling seizures, especially in parenchymal NCC. **Analysis of Options:** * **Praziquantel (Option A):** While effective against many trematodes and cestodes, it has lower CNS penetration compared to Albendazole. It is considered a second-line agent or used in combination with Albendazole for heavy cyst burdens (multicystic disease). * **Levamisole (Option C):** Primarily used as an immunomodulator or for Ascaris infections; it has no role in treating NCC. * **Piperazine (Option D):** An older anthelmintic used for *Ascaris* and *Enterobius* by causing flaccid paralysis of the worm; it is ineffective against cysticercosis. **Clinical Pearls for NEET-PG:** 1. **Steroid Co-administration:** Always administer corticosteroids (e.g., Dexamethasone) before or with Albendazole to prevent inflammatory brain edema caused by the death of the larvae (Herxheimer-like reaction). 2. **Duration:** Treatment typically lasts 8–15 days for parenchymal cysts. 3. **Ocular Cysticercosis:** Albendazole is **contraindicated** in ocular cysticercosis as the inflammatory response to dying larvae can cause permanent blindness. Surgical excision is preferred. 4. **Mechanism:** Albendazole works by inhibiting microtubule synthesis (binding to β-tubulin), leading to glucose depletion and death of the parasite.

Question 4: Ethambutol is safer in a patient with which of the following conditions?

A. Liver disease (Correct Answer)
B. Kidney disease
C. Gout
D. Both liver and kidney disease

Explanation: **Explanation:** The correct answer is **Liver disease** because Ethambutol is primarily excreted unchanged by the kidneys (approx. 80%) and undergoes minimal hepatic metabolism. Unlike other first-line anti-tubercular drugs (HRZ—Isoniazid, Rifampicin, and Pyrazinamide), Ethambutol is **not hepatotoxic**. Therefore, it is the drug of choice or a safer alternative when treating tuberculosis in patients with pre-existing chronic liver disease. **Analysis of Incorrect Options:** * **Kidney disease:** Since Ethambutol is mainly excreted via the renal route, it accumulates in renal failure, increasing the risk of dose-dependent toxicity (optic neuritis). Dosage adjustment or avoidance is necessary in renal impairment. * **Gout:** Ethambutol interferes with the renal excretion of uric acid, leading to **hyperuricemia**. This can precipitate an acute attack of gout, making it unsafe for these patients. * **Both liver and kidney disease:** While safe for the liver, its significant risk in renal failure makes this option incorrect. **High-Yield NEET-PG Pearls:** * **Mechanism of Action:** Inhibits **Arabinosyl transferase**, thereby blocking the synthesis of Arabinogalactan in the mycobacterial cell wall. * **Key Side Effect:** **Retrobulbar Optic Neuritis**, manifesting as decreased visual acuity and **Red-Green color blindness**. It is generally reversible upon discontinuation. * **Monitoring:** Monthly visual acuity and color vision testing are mandatory for patients on Ethambutol. * **Pediatric Note:** It is often avoided in young children (usually <6 years) because they cannot reliably report changes in visual acuity or color perception.

Question 5: Bictegravir was approved by FDA for which of the following indications?

A. Cystic fibrosis
B. Tuberculosis
C. Hypertension
D. Human Immunodeficiency Virus (HIV) (Correct Answer)

Explanation: **Explanation:** **Bictegravir** is a potent, second-generation **Integrase Strand Transfer Inhibitor (INSTI)**. It was FDA-approved in 2018 as part of a fixed-dose combination (Bictegravir/Emtricitabine/Tenofovir Alafenamide) for the treatment of **HIV-1 infection** in both treatment-naïve and virologically suppressed patients. **Mechanism of Action:** Bictegravir works by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration into the host cell genome. This prevents the HIV-1 provirus from replicating. **Analysis of Incorrect Options:** * **A. Cystic Fibrosis:** This is a genetic disorder affecting chloride channels (CFTR). Treatment involves CFTR modulators (e.g., Ivacaftor) and antibiotics for lung infections, but not antiretrovirals. * **B. Tuberculosis:** TB is caused by *Mycobacterium tuberculosis* and is treated with RIPE therapy (Rifampin, Isoniazid, Pyrazinamide, Ethambutol). While HIV and TB are common co-infections, Bictegravir itself has no anti-mycobacterial activity. * **C. Hypertension:** This is managed with ACE inhibitors, ARBs, Beta-blockers, or Calcium channel blockers. **High-Yield Clinical Pearls for NEET-PG:** * **Class:** INSTI (Suffix "-tegravir"). Other members include Dolutegravir, Raltegravir, and Elvitegravir. * **Advantages:** Bictegravir has a **high genetic barrier to resistance** and fewer drug-drug interactions compared to older protease inhibitors or Elvitegravir (which requires boosting with Cobicistat). * **Side Effects:** Generally well-tolerated; may cause headache, GI upset, or weight gain. * **Drug Interaction:** Avoid co-administration with polyvalent cations (Mg, Al, Ca) as they can chelate the drug and reduce absorption.

Practice by Chapter

Beta-Lactam Antibiotics

Practice Questions

Aminoglycosides

Practice Questions

Macrolides and Ketolides

Practice Questions

Tetracyclines

Practice Questions

Quinolones

Practice Questions

Sulfonamides and Trimethoprim

Practice Questions

Antimycobacterial Drugs

Practice Questions

Antifungal Agents

Practice Questions

Antiviral Drugs

Practice Questions

Antiparasitic Agents

Practice Questions

Principles of Antimicrobial Selection

Practice Questions

Antimicrobial Resistance

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free